The VEGF signaling pathway in cancer: the road ahead  

作　　者：Steven A. Stacker Marc G. Achen 

机构地区：[1]Tumour Angiogenesis Program, Peter MacCallum Cancer Centre, St. Andrews Place [2]Sir Peter MacCallum Department of Oncology, University of Melbourne

出　　处：《Chinese Journal of Cancer》2013年第6期297-302,共6页

基　　金：funded partly by a program grant from the National Health and Medical Research Council of Australia(NH&MRC);supported by Senior Research Fellowships from the NH&MRC;support of the Pfizer Australia Fellowship

摘　　要：The vascular endothelial growth factor (VEGF) family of soluble protein growth factors consists of key mediators of angiogenesis and lymphangiogenesis in the context of tumor biology. The members of the family, VEGF-A (also known as VEGF), VEGF-B, VEGF-C, VEGF-D, and placenta growth factor (PlGF), play important roles in vascular biology in both normal physiology and pathology. The generation of a humanized neutralizing antibody to VEGF-A (bevacizumab, also known as Avastin) and the demonstration of its benefit in numerous human cancers have confirmed the merit of an anti-angiogenesis approach to cancer treatment and have validated the VEGF-A signaling pathway as a therapeutic target. Other members of the VEGF family are now being targeted, and their relevance to human cancer and the development of resistance to anti-VEGF-A treatment are being evaluated in the clinic. Here, we discuss the potential of targeting VEGF family members in the diagnosis and treatment of cancer.The vascular endothelial growth factor （VEGF） family of soluble protein growth factors consists of key mediators of angiogenesis and lymphangiogenesis in the context of tumor biology. The members of the family, VEGF-A （also known as VEGF）, VEGF-B, VEGF-C, VEGF-D, and placenta growth factor （PIGF）, play important roles in vascular biology in both normal physiology and pathology. The generation of a humanized neutralizing antibody to VEGF-A （bevacizumab, also known as Avastin） and the demonstration of its benefit in numerous human cancers have confirmed the merit of an anti-angiogenesis approach to cancer treatment and have validated the VEGF-A signaling pathway as a therapeutic target. Other members of the VEGF family are now being targeted, and their relevance to human cancer and the development of resistance to anti-VEGF-A treatment are being evaluated in the clinic. Here, we discuss the potential of targeting VEGF family members in the diagnosis and treatment of cancer.

关 键 词：VEGF-C 癌症治疗 信号通路 血管内皮生长因子 EGF家族 肿瘤生物学 道路 胎盘生长因子 

分 类 号：R730.2[医药卫生—肿瘤]